应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BCAX Bicara Therapeutics
休市中 12-05 16:00:00 EST
18.20
-0.56
-2.99%
盘后
18.20
+0.00
0.00%
17:55 EST
最高
19.18
最低
18.18
成交量
70.37万
今开
18.90
昨收
18.76
日振幅
5.33%
总市值
9.97亿
流通市值
4.39亿
总股本
5,478万
成交额
1,290万
换手率
2.92%
流通股本
2,413万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Bicara Therapeutics:预计现有现金、现金等价物和投资将支持公司运营至2029年上半年
美股速递 · 11-10
Bicara Therapeutics:预计现有现金、现金等价物和投资将支持公司运营至2029年上半年
Bicara Therapeutics Inc.2024财年第三财季实现净利润-17.48百万美元,同比增加23.50%
市场透视 · 2024-11-19
Bicara Therapeutics Inc.2024财年第三财季实现净利润-17.48百万美元,同比增加23.50%
异动解读 | TPG支持的生物科技公司Bicara Therapeutics首次公开募股(IPO)大涨45.8%
异动解读 · 2024-09-14
异动解读 | TPG支持的生物科技公司Bicara Therapeutics首次公开募股(IPO)大涨45.8%
加载更多
公司概况
公司名称:
Bicara Therapeutics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Bicara Therapeutics Inc.于2018年12月12日在特拉华州注册成立。他们是一家临床阶段的生物制药公司,致力于为实体瘤患者带来变革性的双功能疗法。他们的主要项目阿法是一种双功能抗体,它结合了两个临床验证的靶点,即表皮生长因子受体(EGFR)导向的单克隆抗体和结合人类转化生长因子β(TGF-b)的结构域。通过这种双靶向机制,阿法有可能通过同时阻断癌症细胞固有的EGFR存活和增殖,以及肿瘤微环境(TME)中的免疫抑制性TGF-b信号传导,发挥强大的抗肿瘤活性。Ficerafusp alfa通过与肿瘤细胞上的EGFR结合,将TGF-b抑制剂直接引入TME,他们认为这将导致持久的反应和总生存率或OS的增加,同时减少通常与全身TGF-b抑制相关的不良反应。
发行价格:
--
{"stockData":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":18.2,"timestamp":1764968400000,"preClose":18.76,"halted":0,"volume":703696,"hourTrading":{"tag":"盘后","latestPrice":18.2,"preClose":18.2,"latestTime":"17:55 EST","volume":7878,"amount":143376.72,"timestamp":1764975350288},"delay":0,"floatShares":24134001,"shares":54781950,"eps":-2.227112,"marketStatus":"休市中","change":-0.56,"latestTime":"12-05 16:00:00 EST","open":18.9,"high":19.18,"low":18.18,"amount":12896740.035312,"amplitude":0.053305,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.227112,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":18.76,"preHourTrading":{"tag":"盘前","latestPrice":19.1,"preClose":18.76,"latestTime":"08:40 EST","volume":23,"amount":431.67000299999995,"timestamp":1764942047975},"postHourTrading":{"tag":"盘后","latestPrice":18.2,"preClose":18.2,"latestTime":"17:55 EST","volume":7878,"amount":143376.72,"timestamp":1764975350288},"volumeRatio":1.7301722407502242,"impliedVol":0.5509,"impliedVolPercentile":0.576},"requestUrl":"/m/hq/s/BCAX","defaultTab":"news","newsList":[{"id":"1121220229","title":"Bicara Therapeutics:预计现有现金、现金等价物和投资将支持公司运营至2029年上半年","url":"https://stock-news.laohu8.com/highlight/detail?id=1121220229","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121220229?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:39","pubTimestamp":1762778380,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics:预计现有现金、现金等价物和投资将支持公司运营至2029年上半年","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2484130309","title":"Bicara Therapeutics Inc.2024财年第三财季实现净利润-17.48百万美元,同比增加23.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484130309","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484130309?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:00","pubTimestamp":1732010416,"startTime":"0","endTime":"0","summary":"11月19日,Bicara Therapeutics Inc.公布财报,公告显示公司2024财年第三财季净利润为-17.48百万美元,同比增加23.50%;其中营业收入为0.00美元,每股基本收益为-0.32美元。机构评级:截至2024年11月19日,当前有4家机构对Bicara Therapeutics Inc.目标价做出预测,其中目标均价为42.05美元,其中最低目标价为36.00美元,最高目标价为48.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180024abcede94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180024abcede94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCAX","LENZ"],"gpt_icon":0},{"id":"1157360442","title":"异动解读 | TPG支持的生物科技公司Bicara Therapeutics首次公开募股(IPO)大涨45.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157360442","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157360442?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:16","pubTimestamp":1726247788,"startTime":"0","endTime":"0","summary":"9月13日,由风险投资巨头TPG支持的生物科技公司Bicara Therapeutics Inc在纳斯达克上市首日,股价大涨45.8%,引发投资者热捧。Bicara Therapeutics是一家专注于开发创新癌症疗法的生物科技公司。在本次IPO中,公司共发行了1320万股股票,融资2.25亿美元,超出了原计划规模。数据显示,今年美国的IPO市场复苏迹象明显,其中以医疗健康板块为重点领域。有分析认为,Bicara Therapeutics超额认购的成功上市预示着资金青睐具有前景的生物科技创新项目,为行业发展带来了新的契机。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCAX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bicara.com","stockEarnings":[{"period":"1week","weight":-0.0194},{"period":"1month","weight":0.2871},{"period":"3month","weight":0.5091},{"period":"6month","weight":0.5826},{"period":"1year","weight":-0.0686},{"period":"ytd","weight":0.0448}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Bicara Therapeutics Inc.于2018年12月12日在特拉华州注册成立。他们是一家临床阶段的生物制药公司,致力于为实体瘤患者带来变革性的双功能疗法。他们的主要项目阿法是一种双功能抗体,它结合了两个临床验证的靶点,即表皮生长因子受体(EGFR)导向的单克隆抗体和结合人类转化生长因子β(TGF-b)的结构域。通过这种双靶向机制,阿法有可能通过同时阻断癌症细胞固有的EGFR存活和增殖,以及肿瘤微环境(TME)中的免疫抑制性TGF-b信号传导,发挥强大的抗肿瘤活性。Ficerafusp alfa通过与肿瘤细胞上的EGFR结合,将TGF-b抑制剂直接引入TME,他们认为这将导致持久的反应和总生存率或OS的增加,同时减少通常与全身TGF-b抑制相关的不良反应。","exchange":"NASDAQ","name":"Bicara Therapeutics","nameEN":"Bicara Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Bicara Therapeutics(BCAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Bicara Therapeutics,BCAX,Bicara Therapeutics股票,Bicara Therapeutics股票老虎,Bicara Therapeutics股票老虎国际,Bicara Therapeutics行情,Bicara Therapeutics股票行情,Bicara Therapeutics股价,Bicara Therapeutics股市,Bicara Therapeutics股票价格,Bicara Therapeutics股票交易,Bicara Therapeutics股票购买,Bicara Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Bicara Therapeutics(BCAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}